Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Frequency of uMRD in Japanese Patients With CLL After 24 Months of Treatment With Venetoclax±Rituximab in the 2L+ in the Real-World Setting

NCT06362044 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06362044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06362044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Frequency of uMRD in Japanese Patients With CLL After 24 Months of Treatment With Venetoclax±Rituximab in the 2L+ in the Real-World Setting
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
June 7, 2023
Completion date
December 31, 2024
Enrollment
89 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia